MY208974A - Method for preparing influenza ha split vaccine - Google Patents

Method for preparing influenza ha split vaccine

Info

Publication number
MY208974A
MY208974A MYPI2021005035A MYPI2021005035A MY208974A MY 208974 A MY208974 A MY 208974A MY PI2021005035 A MYPI2021005035 A MY PI2021005035A MY PI2021005035 A MYPI2021005035 A MY PI2021005035A MY 208974 A MY208974 A MY 208974A
Authority
MY
Malaysia
Prior art keywords
influenza
split vaccine
stem region
preparing influenza
binds
Prior art date
Application number
MYPI2021005035A
Other languages
English (en)
Inventor
Yoshimasa Takahashi
Yu Adachi
Manabu Ato
Original Assignee
Sumitomo Pharma Co Ltd
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd, Japan As Represented By Director General Of Nat Institute Of Infectious Diseases filed Critical Sumitomo Pharma Co Ltd
Publication of MY208974A publication Critical patent/MY208974A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MYPI2021005035A 2019-03-04 2020-03-03 Method for preparing influenza ha split vaccine MY208974A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (1)

Publication Number Publication Date
MY208974A true MY208974A (en) 2025-06-14

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021005035A MY208974A (en) 2019-03-04 2020-03-03 Method for preparing influenza ha split vaccine

Country Status (15)

Country Link
US (1) US12491240B2 (https=)
EP (1) EP3936147A4 (https=)
JP (1) JP7545955B2 (https=)
KR (1) KR20210135261A (https=)
CN (1) CN114096273B (https=)
AU (1) AU2020233456B2 (https=)
BR (1) BR112021017310A8 (https=)
CA (1) CA3132578A1 (https=)
EA (1) EA202192398A1 (https=)
IL (1) IL285984A (https=)
MX (1) MX2021010685A (https=)
MY (1) MY208974A (https=)
PH (1) PH12021552094A1 (https=)
SG (1) SG11202109566XA (https=)
WO (1) WO2020179797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
MX2022005513A (es) * 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.
EP4703377A1 (en) 2023-04-26 2026-03-04 Japan Institute for Health Security Anti-influenza antibody

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
US20230201329A1 (en) * 2006-07-17 2023-06-29 Glaxosmithkline Biologicals Sa Influenza vaccine
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009115917A2 (en) * 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
WO2010010467A2 (en) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
US8815252B2 (en) * 2008-11-25 2014-08-26 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
CN101524538A (zh) 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011111966A2 (en) 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CN103502263A (zh) 2011-04-21 2014-01-08 巴克斯特国际公司 用于从疫苗离析和量化抗原的方法
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN106794241A (zh) 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
JP2018517405A (ja) * 2015-05-04 2018-07-05 エピバックス インコーポレーテッド インフルエンザａ／上海／２／２０１３ ｈ７配列の改変ｈ７赤血球凝集素糖タンパク質
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
PL3603619T3 (pl) * 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
MY204177A (en) * 2017-09-04 2024-08-14 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Method for producing influenza ha split vaccine
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) * 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CN113194986A (zh) * 2018-12-26 2021-07-30 大日本住友制药株式会社 包括疫苗佐剂的制剂
WO2020176524A1 (en) * 2019-02-28 2020-09-03 Novavax, Inc. Methods for preventing disease or disorder caused by rsv infection

Also Published As

Publication number Publication date
CA3132578A1 (en) 2020-09-10
WO2020179797A1 (ja) 2020-09-10
US20220152191A1 (en) 2022-05-19
AU2020233456A1 (en) 2021-10-07
EP3936147A4 (en) 2022-09-28
MX2021010685A (es) 2021-12-10
EA202192398A1 (ru) 2021-11-23
PH12021552094A1 (en) 2022-05-30
IL285984A (en) 2021-10-31
JPWO2020179797A1 (https=) 2020-09-10
CN114096273A (zh) 2022-02-25
JP7545955B2 (ja) 2024-09-05
BR112021017310A2 (https=) 2021-11-16
BR112021017310A8 (pt) 2022-12-06
KR20210135261A (ko) 2021-11-12
AU2020233456B2 (en) 2026-04-09
US12491240B2 (en) 2025-12-09
SG11202109566XA (en) 2021-10-28
CN114096273B (zh) 2026-03-17
EP3936147A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
PH12020500414A1 (en) Method for producing influenza ha split vaccine
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
MY208974A (en) Method for preparing influenza ha split vaccine
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
PH12019500854A1 (en) Recombinant vectors expressing antigens of avian influenza virus and uses thereof
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
JP2019043937A5 (https=)
PE20181009A1 (es) ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
MD4890B1 (ro) Compoziţie de vaccin combinat, care conţine o doză redusă de poliovirus inactivat, şi procedeu de preparare a acesteia
HK1254522A1 (zh) 灭活的犬流感疫苗以及其制备方法和用途
PH12020500042A1 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
EA202192251A1 (ru) Вакцина для защиты от streptococcus suis
MY204177A (en) Method for producing influenza ha split vaccine
WO2017053525A3 (en) Influenza vaccine and therapy
MX381745B (es) Vacunas de pestivirus para temblores congenitos.
EA201890502A1 (ru) Комбинированная вакцинная композиция для многократного дозирования
MX2022006005A (es) Metodo para producir virus de la influenza reagrupados.
MX2017014146A (es) Glicoproteína de hemaglutinina h7 modificada de la secuencia de influenza a/shanghai/2/2013 h7.